Photodynamic therapy treatment for peripapillary pachychoroi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT).

In this multicentric analysis, 25 eyes from 23 patients with PPS who were treated with PDT were retrospectively assessed. The proportion of eyes that achieved treatment success, characterized as a decrease in both SRF height and central subfield thickness (CST) at 3 months after PDT relative to baseline, was the primary outcome indicator. The improvement in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment, as well as predictive factors for treatment progress, were secondary outcomes. Data from the previous three to twelve months was also analyzed when it was available.

Results:
--Treatment success was achieved in 16 eyes.

--In the total cohort, CST decreased significantly from 356±118 microm at baseline to 282±90 microm and 270±91 microm at 1 and 3 months, respectively.

--Maximal SRF height decreased significantly from 102±83 µm at baseline to 38±46 microm and 32±42 microm at 1 and 3 months, respectively, and remained stable at month 6 and month 12.

--BCVA improved significantly from baseline to month 3.

Finally, PDT can be considered a successful treatment choice for PPS patients. In order to determine the best treatment algorithm for this relatively new disease, prospective data with longer follow-up in a larger cohort is needed.

Source: https://www.nature.com/articles/s41433-021-01515-z?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed:+eye/rss/current+(Eye+-+Issue)
Like
Comment
Share